DTIL
Precision BioSciences, Inc.
Price Chart
Latest Quote
$6.81
+0.31 (+4.77%)
Current Price
| Previous Close | $6.50 |
| Open | $6.63 |
| Day High | $6.98 |
| Day Low | $6.52 |
| Volume | 431,066 |
Stock Information
| Shares Outstanding | 25.80M |
| Total Debt | $28.47M |
| Cash Equivalents | $101.18M |
| Revenue | $45.07M |
| Net Income | $-44.48M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $175.71M |
| EPS (TTM) | $-2.18 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $103.00M |
| Sales | $45.07M |
| Income | $-44.48M |
| Book/sh | $2.95 |
| Cash/sh | $3.92 |
| Employees | 66 |
Financial Ratios
| Quick Ratio | 13.56 |
| Current Ratio | 14.02 |
| Debt/Eq | 37.41 |
Returns & Margins
| ROA | -18.22% |
| ROE | -70.93% |
| Gross Margin | 100.00% |
| Operating Margin | -83.73% |
| Profit Margin | -96.73% |
Ownership
| Insider Ownership | 6.44% |
| Institutional Ownership | 65.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.60 |
| P/S | 3.90 |
| P/B | 2.31 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $29.60 |
Technical Indicators
| SMA20 | $6.70 |
| SMA50 | $7.12 |
| SMA200 | $5.65 |
| RSI | 47.59 |
| ATR | 0.5831 |
| Shares Float | 20.01M |
| Short Float | 6.66% |
| Short Ratio | 5.74 |
| Volatility | 1.28 |
| Rel Volume | 1.15 |
Performance History
| Week | +10.37% |
| Month | -1.30% |
| Quarter | +1.34% |
| 6 Months | +41.29% |
| YTD | +66.10% |
| Year | +38.98% |
| 3 Years | -68.03% |
| 5 Years | -98.03% |
| 10 Years | -98.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.81 | 431,100 |
| 2026-06-17 | $6.50 | 212,600 |
| 2026-06-16 | $6.31 | 209,200 |
| 2026-06-15 | $6.21 | 144,300 |
| 2026-06-12 | $6.10 | 236,000 |
| 2026-06-11 | $6.17 | 432,200 |
| 2026-06-10 | $6.45 | 318,600 |
| 2026-06-09 | $6.86 | 558,700 |
| 2026-06-08 | $6.77 | 842,500 |
| 2026-06-05 | $6.50 | 253,200 |
| 2026-06-04 | $6.41 | 196,600 |
| 2026-06-03 | $6.04 | 234,500 |
| 2026-06-02 | $6.32 | 461,600 |
| 2026-06-01 | $7.02 | 313,600 |
| 2026-05-29 | $6.97 | 266,200 |
| 2026-05-28 | $6.92 | 612,400 |
| 2026-05-27 | $7.59 | 952,800 |
| 2026-05-26 | $7.58 | 494,000 |
| 2026-05-22 | $7.23 | 179,900 |
| 2026-05-21 | $7.15 | 129,600 |
| 2026-05-20 | $7.18 | 176,800 |
| 2026-05-19 | $6.90 | 189,500 |
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
đ° Latest News
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Simply Wall St. âĸ 2026-05-13T11:07:46Z
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-05T12:25:04Z
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
Zacks âĸ 2026-04-27T12:18:00Z
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-04-20T11:59:00Z
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
Zacks âĸ 2026-04-14T13:55:01Z
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Zacks âĸ 2026-03-12T12:15:01Z
Precision BioSciences: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-12T11:15:01ZCoherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-09T21:35:02Z
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio
Simply Wall St. âĸ 2026-03-08T20:11:18Z
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story
Simply Wall St. âĸ 2026-03-08T18:11:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $34,264,000 | $68,696,000 | $48,727,000 | $25,098,000 |
| Operating Revenue | $34,264,000 | $68,696,000 | $48,727,000 | $25,098,000 |
| Expenses | ||||
| Interest Expense | $1,422,000 | $1,782,000 | $2,230,000 | $1,111,000 |
| Total Expenses | $86,412,000 | $94,858,000 | $92,463,000 | $87,406,000 |
| Other Income Expense | $2,722,000 | $28,348,000 | $-4,247,000 | $-12,963,000 |
| Other Non Operating Income Expenses | $-2,666,000 | $258,000 | $1,145,000 | - |
| Net Non Operating Interest Income Expense | $2,817,000 | $4,981,000 | $5,456,000 | $2,362,000 |
| Interest Expense Non Operating | $1,422,000 | $1,782,000 | $2,230,000 | $1,111,000 |
| Operating Expense | $86,412,000 | $94,858,000 | $92,463,000 | $87,406,000 |
| General And Administrative Expense | $32,240,000 | $35,299,000 | $39,088,000 | $41,284,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-46,609,000 | $7,167,000 | $-42,527,000 | $-72,909,000 |
| Net Interest Income | $2,817,000 | $4,981,000 | $5,456,000 | $2,362,000 |
| Interest Income | $4,239,000 | $6,763,000 | $7,686,000 | $3,473,000 |
| Normalized Income | $-57,281,000 | $-15,880,460 | $-42,066,000 | $-61,525,000 |
| Net Income From Continuing And Discontinued Operation | $-45,724,000 | $7,167,000 | $-61,319,000 | $-111,637,000 |
| Total Operating Income As Reported | $-52,148,000 | $-26,162,000 | $-43,736,000 | $-62,308,000 |
| Net Income Common Stockholders | $-45,724,000 | $7,167,000 | $-61,319,000 | $-111,637,000 |
| Net Income | $-45,724,000 | $7,167,000 | $-61,319,000 | $-111,637,000 |
| Net Income Including Noncontrolling Interests | $-45,724,000 | $7,167,000 | $-61,319,000 | $-111,637,000 |
| Net Income Discontinuous Operations | $885,000 | $0 | $-18,792,000 | $-38,728,000 |
| Net Income Continuous Operations | $-46,609,000 | $7,167,000 | $-42,527,000 | $-72,909,000 |
| Pretax Income | $-46,609,000 | $7,167,000 | $-42,527,000 | $-72,909,000 |
| Special Income Charges | $-457,000 | $-436,000 | $-461,000 | $-10,874,000 |
| Earnings From Equity Interest | $-5,284,000 | $-1,084,000 | $-4,931,000 | $-1,579,000 |
| Interest Income Non Operating | $4,239,000 | $6,763,000 | $7,686,000 | $3,473,000 |
| Operating Income | $-52,148,000 | $-26,162,000 | $-43,736,000 | $-62,308,000 |
| Per Share | ||||
| Diluted EPS | $-3.56 | $1.04 | $-15.96 | $-38.10 |
| Basic EPS | $-3.56 | $1.05 | $-15.96 | $-38.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $6,126,540 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-53,106,000 | $-15,648,000 | $-31,581,000 | $-51,410,000 |
| Total Unusual Items | $10,672,000 | $29,174,000 | $-461,000 | $-11,384,000 |
| Total Unusual Items Excluding Goodwill | $10,672,000 | $29,174,000 | $-461,000 | $-11,384,000 |
| Reconciled Depreciation | $2,753,000 | $4,577,000 | $8,255,000 | $9,004,000 |
| EBITDA (Bullshit earnings) | $-42,434,000 | $13,526,000 | $-32,042,000 | $-62,794,000 |
| EBIT | $-45,187,000 | $8,949,000 | $-40,297,000 | $-71,798,000 |
| Diluted Average Shares | $12,826,078 | $6,883,911 | $3,841,405 | $2,929,949 |
| Basic Average Shares | $12,826,078 | $6,832,982 | $3,841,405 | $2,929,949 |
| Diluted NI Availto Com Stockholders | $-45,724,000 | $7,167,000 | $-61,319,000 | $-111,637,000 |
| Gain On Sale Of Ppe | $-421,000 | $-436,000 | $-461,000 | $-30,000 |
| Impairment Of Capital Assets | $36,000 | $0 | $0 | $10,844,000 |
| Gain On Sale Of Security | $11,129,000 | $29,610,000 | $1,145,000 | $-510,000 |
| Research And Development | $54,172,000 | $59,559,000 | $53,375,000 | $46,122,000 |
| Selling General And Administration | $32,240,000 | $35,299,000 | $39,088,000 | $41,284,000 |
| Other Gand A | $32,240,000 | $35,299,000 | $39,088,000 | $41,284,000 |
| Write Off | - | - | $0 | $10,844,000 |
| Gain On Sale Of Business | - | - | - | $0 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $91,082,000 | $55,771,000 | $18,461,000 | $59,702,000 |
| Total Assets | $154,416,000 | $136,388,000 | $159,781,000 | $238,169,000 |
| Total Non Current Assets | $35,676,000 | $41,399,000 | $23,422,000 | $39,064,000 |
| Other Non Current Assets | $26,536,000 | $22,790,000 | $225,000 | $12,572,000 |
| Non Current Note Receivables | $0 | $4,602,000 | $4,990,000 | $7,234,000 |
| Investmentin Financial Assets | $744,000 | $3,206,000 | $3,206,000 | $2,576,000 |
| Goodwill And Other Intangible Assets | $1,166,000 | $622,000 | $400,000 | $731,000 |
| Other Intangible Assets | $1,166,000 | $622,000 | $400,000 | $731,000 |
| Current Assets | $118,740,000 | $94,989,000 | $136,359,000 | $199,105,000 |
| Other Current Assets | $45,000 | $369,000 | $419,000 | $1,228,000 |
| Assets Held For Sale Current | $0 | $169,000 | $487,000 | $1,556,000 |
| Prepaid Assets | $3,110,000 | $6,441,000 | $5,977,000 | $6,025,000 |
| Receivables | $0 | $1,698,000 | $12,798,000 | $720,000 |
| Accounts Receivable | $0 | $229,000 | $901,000 | $720,000 |
| Cash Cash Equivalents And Short Term Investments | $115,585,000 | $86,312,000 | $116,678,000 | $189,576,000 |
| Cash And Cash Equivalents | $110,823,000 | $85,899,000 | $116,678,000 | $189,576,000 |
| Other Receivables | - | $1,469,000 | - | - |
| Notes Receivable | - | $0 | $11,897,000 | $0 |
| Debt | ||||
| Total Debt | $28,808,000 | $30,045,000 | $31,268,000 | $24,960,000 |
| Long Term Debt And Capital Lease Obligation | $27,301,000 | $28,725,000 | $7,723,000 | $23,282,000 |
| Long Term Debt | $22,404,000 | $22,321,000 | - | $22,223,000 |
| Current Debt And Capital Lease Obligation | $1,507,000 | $1,320,000 | $23,545,000 | $1,678,000 |
| Current Debt | - | - | $22,412,000 | - |
| Other Current Borrowings | - | - | $22,412,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $62,168,000 | $79,995,000 | $140,920,000 | $177,736,000 |
| Total Non Current Liabilities Net Minority Interest | $53,255,000 | $65,015,000 | $90,933,000 | $118,072,000 |
| Other Non Current Liabilities | $259,000 | $194,000 | $128,000 | $201,000 |
| Derivative Product Liabilities | $15,695,000 | $2,796,000 | $0 | - |
| Non Current Deferred Liabilities | $10,000,000 | $33,300,000 | $83,082,000 | $92,872,000 |
| Current Liabilities | $8,913,000 | $14,980,000 | $49,987,000 | $59,664,000 |
| Other Current Liabilities | $649,000 | $2,193,000 | $4,904,000 | $4,210,000 |
| Current Deferred Liabilities | $0 | $2,957,000 | $12,035,000 | $46,192,000 |
| Payables And Accrued Expenses | $2,010,000 | $3,328,000 | $4,525,000 | $2,480,000 |
| Payables | $296,000 | $1,312,000 | $2,968,000 | $653,000 |
| Accounts Payable | $296,000 | $1,312,000 | $2,968,000 | $653,000 |
| Liabilities Heldfor Sale Non Current | - | - | $128,000 | $1,717,000 |
| Equity | ||||
| Common Stock Equity | $92,248,000 | $56,393,000 | $18,861,000 | $60,433,000 |
| Total Equity Gross Minority Interest | $92,248,000 | $56,393,000 | $18,861,000 | $60,433,000 |
| Stockholders Equity | $92,248,000 | $56,393,000 | $18,861,000 | $60,433,000 |
| Retained Earnings | $-528,188,000 | $-482,464,000 | $-489,631,000 | $-428,312,000 |
| Long Term Equity Investment | - | - | $0 | $2,172,000 |
| Investments In Other Ventures Under Equity Method | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $26,921 | $27,015 | $27,014 | $27,015 |
| Ordinary Shares Number | $24,088,425 | $8,202,715 | $4,164,037 | $3,698,801 |
| Share Issued | $24,115,346 | $8,229,730 | $4,191,051 | $3,725,816 |
| Tangible Book Value | $91,082,000 | $55,771,000 | $18,461,000 | $59,702,000 |
| Invested Capital | $114,652,000 | $78,714,000 | $41,273,000 | $82,656,000 |
| Working Capital | $109,827,000 | $80,009,000 | $86,372,000 | $139,441,000 |
| Capital Lease Obligations | $6,404,000 | $7,724,000 | $8,856,000 | $2,737,000 |
| Total Capitalization | $114,652,000 | $78,714,000 | $18,861,000 | $82,656,000 |
| Treasury Stock | $952,000 | $952,000 | $952,000 | $952,000 |
| Additional Paid In Capital | $621,387,000 | $539,808,000 | $509,443,000 | $489,696,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $10,000,000 | $33,300,000 | $83,082,000 | $92,872,000 |
| Long Term Capital Lease Obligation | $4,897,000 | $6,404,000 | $7,723,000 | $1,059,000 |
| Current Deferred Revenue | $0 | $2,957,000 | $12,035,000 | $46,192,000 |
| Current Capital Lease Obligation | $1,507,000 | $1,320,000 | $1,133,000 | $1,678,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,747,000 | $5,182,000 | $4,978,000 | $5,104,000 |
| Current Accrued Expenses | $1,714,000 | $2,016,000 | $1,557,000 | $1,827,000 |
| Investments And Advances | $744,000 | $3,206,000 | $3,206,000 | $4,748,000 |
| Available For Sale Securities | $744,000 | $3,206,000 | $3,206,000 | $2,576,000 |
| Net PPE | $7,230,000 | $10,179,000 | $14,601,000 | $13,779,000 |
| Accumulated Depreciation | $-28,692,000 | $-28,076,000 | $-25,488,000 | $-21,869,000 |
| Gross PPE | $35,922,000 | $38,255,000 | $40,089,000 | $35,648,000 |
| Leases | $12,064,000 | $12,028,000 | $11,945,000 | $11,946,000 |
| Construction In Progress | $0 | $9,000 | $70,000 | $520,000 |
| Other Properties | $19,816,000 | $22,176,000 | $24,119,000 | $19,235,000 |
| Machinery Furniture Equipment | $4,042,000 | $4,042,000 | $3,955,000 | $3,947,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $4,762,000 | $413,000 | $0 | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-66,543,000 | $-58,720,000 | $-86,392,000 | $-49,072,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-65,843,000 | $-58,445,000 | $-84,114,000 | $-45,753,000 |
| Cash Flow From Continuing Operating Activities | $-65,843,000 | $-58,445,000 | $-84,114,000 | $-45,753,000 |
| Operating Gains Losses | $-6,279,000 | $-28,090,000 | $-2,952,000 | $1,685,000 |
| Investing Activities | ||||
| Capital Expenditure | $-700,000 | $-275,000 | $-2,278,000 | $-3,319,000 |
| Investing Cash Flow | $-634,000 | $-215,000 | $5,829,000 | $-3,319,000 |
| Cash Flow From Continuing Investing Activities | $-634,000 | $-215,000 | $5,829,000 | $-3,319,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $94,944,000 | $50,238,000 | $4,986,000 | $74,345,000 |
| Financing Cash Flow | $95,162,000 | $50,450,000 | $5,387,000 | $94,985,000 |
| Cash Flow From Continuing Financing Activities | $95,162,000 | $50,450,000 | $5,387,000 | $94,985,000 |
| Net Common Stock Issuance | $94,944,000 | $50,238,000 | $4,986,000 | $74,345,000 |
| Common Stock Issuance | $94,944,000 | $50,238,000 | $4,986,000 | $74,345,000 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-22,505,000 | $0 | $0 |
| Issuance Of Debt | $0 | $22,468,000 | $0 | $19,805,000 |
| Interest Paid Supplemental Data | $1,355,000 | $1,738,000 | $2,018,000 | $824,000 |
| End Cash Position | $137,153,000 | $108,468,000 | $116,678,000 | $189,576,000 |
| Beginning Cash Position | $108,468,000 | $116,678,000 | $189,576,000 | $143,663,000 |
| Changes In Cash | $28,685,000 | $-8,210,000 | $-72,898,000 | $45,913,000 |
| Proceeds From Stock Option Exercised | $218,000 | $249,000 | $401,000 | $835,000 |
| Net Issuance Payments Of Debt | $0 | $-37,000 | $0 | $19,805,000 |
| Net Long Term Debt Issuance | $0 | $-37,000 | $0 | $0 |
| Long Term Debt Payments | $0 | $-22,505,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $22,468,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-615,000 | $-25,000 | $-321,000 | $0 |
| Purchase Of Intangibles | $-615,000 | $-25,000 | $-321,000 | $0 |
| Net PPE Purchase And Sale | $-19,000 | $-190,000 | $-1,850,000 | $-3,319,000 |
| Sale Of PPE | $66,000 | $60,000 | $107,000 | $0 |
| Purchase Of PPE | $-85,000 | $-250,000 | $-1,957,000 | $-3,319,000 |
| Change In Working Capital | $-29,244,000 | $-53,999,000 | $-41,487,000 | $24,110,000 |
| Change In Other Working Capital | $-30,793,000 | $-56,870,000 | $-43,947,000 | $27,358,000 |
| Change In Other Current Liabilities | $-3,082,000 | $-3,260,000 | $-1,670,000 | $-3,638,000 |
| Change In Other Current Assets | $339,000 | $-262,000 | $1,752,000 | $1,431,000 |
| Change In Payables And Accrued Expense | $-737,000 | $-2,096,000 | $1,508,000 | $153,000 |
| Change In Payable | $-737,000 | $-2,096,000 | $1,508,000 | $153,000 |
| Change In Account Payable | $-737,000 | $-2,096,000 | $1,508,000 | $153,000 |
| Change In Prepaid Assets | $3,331,000 | $-464,000 | $1,051,000 | $-962,000 |
| Change In Receivables | $1,698,000 | $8,953,000 | $-181,000 | $-232,000 |
| Changes In Account Receivables | $229,000 | $672,000 | $-181,000 | $-232,000 |
| Other Non Cash Items | $2,429,000 | $-704,000 | $-147,000 | $450,000 |
| Stock Based Compensation | $10,186,000 | $12,604,000 | $14,040,000 | $19,197,000 |
| Asset Impairment Charge | $36,000 | $0 | $641,000 | $11,438,000 |
| Depreciation Amortization Depletion | $2,753,000 | $4,577,000 | $8,255,000 | $9,004,000 |
| Depreciation And Amortization | $2,753,000 | $4,577,000 | $8,255,000 | $9,004,000 |
| Depreciation | $2,753,000 | $4,577,000 | $8,255,000 | $9,004,000 |
| Earnings Losses From Equity Investments | $5,284,000 | $1,084,000 | $4,931,000 | $1,579,000 |
| Gain Loss On Investment Securities | $-11,129,000 | $-29,610,000 | - | - |
| Gain Loss On Sale Of Business | $-855,000 | $0 | $-8,446,000 | $0 |
| Net Income From Continuing Operations | $-45,724,000 | $7,167,000 | $-61,319,000 | $-111,637,000 |
| Net Business Purchase And Sale | - | $0 | $8,000,000 | $0 |
| Sale Of Business | - | $0 | $8,000,000 | $0 |
| Unrealized Gain Loss On Investment Securities | - | $-258,000 | $-1,145,000 | - |
| Net Short Term Debt Issuance | - | - | $0 | $19,805,000 |
| Short Term Debt Issuance | - | - | $0 | $19,805,000 |
Fetched: 2026-06-19